I think lower doses will be for weight/dose ratio (200mg for kids >8yr old). They have stated 800mg target dose, a starting dose of 400mg & titrated up, but what you are saying is right HS, will that be sustainable with AEs like increased oedema & BP, even in a paediatric dose? Sparensan is a new drug, Ibersartan has been around for many years & rather predictable in so many studies & being SOC for FSGS. This is something we would be trying to reduce - oedema with treatment.
Oct 2, page-48
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.5¢ |
Change
-0.010(2.02%) |
Mkt cap ! $270.2M | |||
| Open | High | Low | Value | Volume |
| 50.0¢ | 50.0¢ | 47.5¢ | $772.1K | 1.587M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17961 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 5999 | 1 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |